- $11.48m
- $5.97m
- $3.95m
- 27
- 18
- 45
- 19
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.27 | ||
| Price to Tang. Book | 2.27 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.9 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -498.01% | ||
| Return on Equity | -462.31% | ||
| Operating Margin | -635.83% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.82 | 0.39 | 0.08 | n/a | 3.95 | 7.73 | 6.3 | 27.45% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using proprietary platforms. Its product pipeline includes ongoing human clinical trials for a Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Its additional research and development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan and Marburg), Zika virus and malaria, as well as immunotherapies for multiple solid tumors. The Company’s portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 155 granted or pending patent applications spread over 24 patent families. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02 and others. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations.
Directors
- David Dodd CHM (71)
- Mark Reynolds CFO (59)
- Mark Newman CSO (66)
- Harriet Robinson CSO (81)
- Robert McNally DRC (73)
- Randal Chase IND (71)
- Dean Kollintzas IND (48)
- John Spencer IND (80)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 17th, 2008
- Public Since
- April 4th, 1994
- No. of Shareholders
- 24
- No. of Employees
- 17
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 13,839,478
- Address
- 1900 Lake Park Drive, Suite 380, SMYRNA, 30080
- Web
- https://www.geovax.com/
- Phone
- +1 6783847220
- Auditors
- Wipfli LLP
Upcoming Events for GOVX
GeoVax Labs Inc Annual Shareholders Meeting
GeoVax Labs Inc Annual Shareholders Meeting
Q2 2025 GeoVax Labs Inc Earnings Release
Similar to GOVX
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Geovax Labs share price?
As of Today at 20:48 UTC, shares in Geovax Labs are trading at $0.83. This share price information is delayed by 15 minutes.
How has the Geovax Labs share price performed this year?
Shares in Geovax Labs last closed at $0.83 and the price had moved by -43.18% over the past 365 days. In terms of relative price strength the Geovax Labs share price has underperformed the S&P500 Index by -46.58% over the past year.
What are the analyst and broker recommendations for Geovax Labs?
The overall consensus recommendation for Geovax Labs is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Geovax Labs dividend yield?
Geovax Labs does not currently pay a dividend.
Does Geovax Labs pay a dividend?
Geovax Labs does not currently pay a dividend.
When does Geovax Labs next pay dividends?
Geovax Labs does not currently pay a dividend.
How do I buy Geovax Labs shares?
To buy shares in Geovax Labs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Geovax Labs?
As of the previous close price of $0.83, shares in Geovax Labs had a market capitalisation of $11.48m.
Where are Geovax Labs shares listed?
Here are the trading details for Geovax Labs:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: GOVX
What kind of share is Geovax Labs?
Based on an overall assessment of its quality, value and momentum Geovax Labs is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Geovax Labs share price forecast for 2025?
The analyst consensus target price for shares in Geovax Labs is $12.10. That is 1358.71% above the last closing price of $0.83.
Analysts covering Geovax Labs currently have a consensus Earnings Per Share (EPS) forecast of -$1.88 for the next financial year.
Find out moreWhat is the trend in the Geovax Labs share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Geovax Labs. Over the past six months, its share price has underperformed the S&P500 Index by -56.64%.
As of the last closing price of $0.83, shares in Geovax Labs were trading -65.36% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Geovax Labs PE Ratio?
The Geovax Labs PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.83.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Geovax Labs?
Geovax Labs' management team is headed by:
- David Dodd - CHM
- Mark Reynolds - CFO
- Mark Newman - CSO
- Harriet Robinson - CSO
- Robert McNally - DRC
- Randal Chase - IND
- Dean Kollintzas - IND
- John Spencer - IND